Meds, Mind, Body & Benefits > Research News & Studies

Genetic Immunity® Announces First Patient Dosed In Phase II Trial With DermaVir

(1/1)

HALOO:
http://www.businesswire.com/portal/site/home/permalink/?ndmViewId=news_view&newsId=20081113006456&newsLang=en

http://clinicaltrials.gov/ct2/show/NCT00711230

Navigation

[0] Message Index